Barriguete HJ

Language: Spanish
References: 12
Page: 175-179
PDF size: 92.63 Kb.

ABSTRACT

This is the report of a case of a patient who presented her first psychotic episode at the age of 48 years old with a predominance of delusional symptoms but with a torpid and severe family and social dysfunction meriting psychiatric hospitalization for 83 days because of her difficult treatment and a considerable multiple pharmacological schemes that interfere on the diagnosis and prognosis; the importance of the approach and the differential diagnosis that has to be taken into account to the variety of psychotic symptoms that are part of the diagnosis of schizophrenia, but they certainly are not pathognomonic of it.

REFERENCES

1. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999; 46(7):899-907.

2. Johannessen J, Martindale B, Culberg J. Evolución de las psicosis. Barcelona: Herder; 2008.

3. Manual Diagnóstico y Estadístico de los Trastornos Mentales, cuarta edición revisada, DSM-IV-TR. WPA. Barcelona; Masson; 2003.

4. Falloon IR, Montero I, Sungur M, Mastroeni A, Malm U, Economou M, et al. Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment. World Psychiatry. 2004;3(2):104-9.

5. Practice guideline for the treatment of patients with schizophrenia [monografía en Internet]. American Psychiatric Association; 2004 [citado 2006].

6. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005; 50 (13 Suppl 1):7S-57S.

7. APA Practice Guideline Development Process [monografía en Internet]. Arlington, VA (US): The American Psychiatric Association (APA); 2004. Disponible en: http://www.psych.org

8. Moore TA, Covell NH, Essock SM, Miller AL. Real-world antipsychotic treatment practices. Psychiatr Clin North Am. 2007; 30(3):401-16.

9. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-87.

10. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657):31-41.

11. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD000076. DOI: 10.1002/14651858.CD000076.pub2.

12. Bertolín Guillén JM, Sáez AC, Hernández de Pablo ME, Peiró MS. Eficacia de la terapia electroconvulsiva: revisión sistemática de las evidencias científicas. Actas Esp Psiquiatr. 2004; 32(3):153-65.